65,437 trials
Post-traumatic Osteoarthritis, Unspecified Ankle and Foot · Localized, Primary Osteoarthritis of the Ankle and/or Foot
Primary: Number of Participants With Intraoperative Complications — 0 Participants
Stroke
Primary: Change in Action Research Arm Test Score From Baseline to 3 Months — 23.5; 24; 15.1 score on a scale
Kidney Transplant
Primary: Percent of Patients With at Least One Inquiry From a Potential Living Donor — 15.63; 15.63; 15.77; 15.87 percentage of participants
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Healthy
Primary: PK Profile - Half-life (t½) — 1.07; 0.55; 1.02; 0.68 Days
Nausea With Vomiting Chemotherapy-Induced
Primary: Complete Acute Response — 4; 4; 3 Participants
Major Depressive Disorder
Primary: Proportion of Patients Who Completed Patient Health Questionnaire — 35; 49 participants
Chronic Pain
Primary: Opioid Tapering Success — 86; 61; 81; 0 Participants
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Dental Cements · Caries,Dental
Primary: Functional Long-term Properties Clinical Performance of Restorations (Onlays and Crowns) [Retention Scores] — 40; 40; 0; 0 Restorations
Healthy Participants
Primary: Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling — 666.4; 745.5 Nanogram*hour per milliliter…
Prostate Cancer · Non-metastatic Prostate Cancer · Prostate Adenocarcinoma
Primary: Pilot: Acceptance of Randomisation to Allocated Arm Within CHRONOS A & CHRONOS B — 4; 0; 11; 10 Participants
Glioblastoma, Adult
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 2 Participants
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Procedure and/or Product Related Adverse Events — 70.0; 60.0; 30.0; 20.0 percent of participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs): SAD Cohort — 4; 1; 1; 3 Participants